98 related articles for article (PubMed ID: 10979901)
1. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.
Jacobson MA; Hardy D; Connick E; Watson J; DeBruin M
J Infect Dis; 2000 Oct; 182(4):1070-6. PubMed ID: 10979901
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
Jacobson JM; Lederman MM; Spritzler J; Valdez H; Tebas P; Skowron G; Wang R; Jackson JB; Fox L; Landay A; Gilbert MJ; O'Neil D; Bancroft L; Al-Harthi L; Jacobson MA; Merigan TC; Glesby MJ;
J Infect Dis; 2003 Dec; 188(12):1804-14. PubMed ID: 14673758
[TBL] [Abstract][Full Text] [Related]
3. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
Gori A; Trabattoni D; Bandera A; Saresella M; Marchetti G; Gazzola L; Biasin M; Rhodes J; McDade H; Panebianco R; Galli M; Moroni M; Ferrante P; Thomas N; Franzetti F; Bray D; Clerici M
Antivir Ther; 2004 Aug; 9(4):603-14. PubMed ID: 15456092
[TBL] [Abstract][Full Text] [Related]
5. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
7. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
8. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
Jacobson MA; Spritzler J; Landay A; Chan E; Katzenstein D; Schock B; Fox L; Roe J; Kundu S; Pollard R;
AIDS; 2002 May; 16(8):1147-54. PubMed ID: 12004273
[TBL] [Abstract][Full Text] [Related]
9. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
13. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
16. Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients.
Bassani S; López M; Toro C; Jiménez V; Sempere JM; Soriano V; Benito JM
Clin Infect Dis; 2007 Jan; 44(1):105-10. PubMed ID: 17143825
[TBL] [Abstract][Full Text] [Related]
17. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
[TBL] [Abstract][Full Text] [Related]
18. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
19. [The role of therapeutic use of interleukin-2 in HIV infection].
Knysz B; Gasiorowski J; Inglot M; Rymer W; Szymczak A; Gładysz A
Przegl Epidemiol; 2002; 56(4):587-93. PubMed ID: 12666584
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
